


## II. AMENDMENTS TO THE CLAIMS

Please cancel claims 2, 4, 6, and 8.

*difference  
to parent*

Claim 1 (Currently Amended) ~~A method of administering a compound of the formula~~ A method of treating or preventing a neoplasia disease sensitive to the combination comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:






wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

*PS  
12/03*





Claim 2 (Cancelled)







Claim 3 (Currently Amended) A method according to Claim 1 wherein the compound is selected from the group consisting of:






Cu2








Claim 4 (Cancelled)

Claim 5 (Currently Amended) A method of treating or preventing a neoplasia disease sensitive to the combination comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:








wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel,



PS  
12/03

mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.





Claim 6 (Cancelled)



Claim 7 (Currently Amended) A method according to Claim 5 wherein the compound is selected from the group consisting of:








Ca





02



Claim 8 (Cancelled)

Claim 9 (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1, a

①  
Composition  
dep.  
from method

AS  
12/13  
chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine, and a pharmaceutically acceptable carrier.

ad  
Claim 10 (Original) A method according to claim 5 wherein the neoplasia disease is tumor metastasis.

Claim 11 (Original) A method according to claim 5 wherein the neoplasia disease is solid tumor growth.

Claim 12 (Original) A method according to claim 5 wherein the neoplasia disease is angiogenesis.

Claim 13 (Original) A method according to claim 5 wherein the neoplasia disease is humoral hypercalcemia of malignancy.

---